Data from Randomized Phase II Study of Durvalumab...

Data from Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Abstract

<div>AbstractPurpose:<p>PD-L1 is overexpressed by dendritic cells in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on androgen receptor pathway inhibitors. We tested whether checkpoint blockade could enhance antitumor activity in mCRPC.</p>Patients and Methods:<p>In a multicenter open-label noncomparative randomized phase II study, patients with mCRPC treated with ≤1 prior cytotoxic chemotherapy, with measurable disease and progression on abiraterone and/or enzalutamide, were randomized to durvalumab 1,500 mg intravenously every 4 weeks ±4 doses of tremelimumab 75 mg intravenously. The primary endpoint was objective response (OR) by iRECIST using a Simon two-stage design. Correlative testing included PD-L1/cluster designation 8 IHC on baseline tumor biopsies and deep targeted sequencing of plasma cell–free DNA.</p>Results:<p>Fifty-two patients were enrolled. Median age was 70 years (range, 50–83 years), and 52% had prior taxane therapy for mCRPC. In stage I, 13 patients were randomized to durvalumab with no OR observed. Durvalumab + tremelimumab advanced to stage II with 39 patients enrolled (receiving a median three cycles, range 1–53). Durvalumab + tremelimumab–related adverse events were mainly ≤ grade 2 but led to discontinuation in seven patients. There were seven ORs [19.4% (95% confidence interval: 8.2%–36.0%); intention to treat 17.9% (95% confidence interval: 7.5%–33.5%)]. Five responding tumors were PD-L1–positive and two exhibited DNA damage repair defects. Responses were observed without high tumor mutational burden or other genomic indices of immunotherapy sensitivity.</p>Conclusions:<p>Durvalumab + tremelimumab is active in mCRPC, but patient selection remains a challenge. Further studies to develop predictive biomarkers are warranted.</p></div>

Authors

Winquist E; Hotte SJ; Chi K; Sridhar S; Ellard S; Ong M; Iqbal N; Salim M; Emmenegger U; Gingerich JR

Publication Date

January 6, 2025

DOI

10.1158/1078-0432.c.7611414

Associated Experts

Aly-Khan Lalani

Associate Professor, Faculty of Health Sciences

Visit profile

Sebastien Hotte

Professor, Faculty of Health Sciences

Visit profile

View published work (Non-McMaster Users)

Contact the Experts team

Get technical help

Provide website feedback